secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0000950170-25-099631
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M
--------------------------------------------------------------------------------

- Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.
- Onvansertib well-tolerated; neutropenia most common grade 3+ AE; no unexpected toxicities.
- Q2 operating expenses $14.9M (vs $12.7M); cash and investments $71.0M; runway into Q1 2027.
- Appointed Dr. Roger Sidhu as CMO; completed enrollment in 41-site CRDF-004 trial.
- Company expects to provide update on first-line mCRC program by Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025099631/0000950170-25-099631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025099631/crdf-20250729.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-099631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer